Why is "Centanafadine" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-28 19:06:08
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Centanafadine (INN; former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC50 ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of 24 November 2025, Otsuka's pipeline indicates it is in phase II and III clinical trials for a number of different applications to medical conditions.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
FDA Fast-Tracks Otsuka’s Novel ADHD Drug - Psychiatrist.com
-
Centanafadine: A Novel Triple Reuptake Inhibitor for the Treatment of ADHD in Adolescents - mghpsychnews.org
-
FDA Grants Priority Review to Centanafadine for ADHD - MPR - Medical Professionals Reference
-
Centanafadine for Treatment of ADHD in Children, Adolescents, and Adults Accepted By FDA for Priority Review - Pharmacy Times
-
FDA accepts Otsuka’s centanafadine application for ADHD treatment - Pharmaceutical Technology
-
ADHD Non-Stimulant Triple Reuptake Inhibitor Seeks FDA Approval - ADDitude
-
Centanafadine Pharmacological Profile Affirms Potential for Treatment of ADHD - Psychiatric Times
-
Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan - Patient Care Online
-
FDA accepts centanafadine NDA for priority review for ADHD in children, adolescents - Contemporary Pediatrics
-
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children - HCPLive
-
Otsuka preps for July decision on centanafadine for ADHD - pharmaphorum
-
Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults - BioSpace
-
Centanafadine ‘Clinically Meaningful’ for Adult ADHD - Medscape
-
FDA Accepts NDA for Priority Review: Centanafadine for Treatment of ADHD - Psychiatric Times
-
Otsuka Seeks FDA Approval for New ADHD Drug - Psychiatrist.com
-
Centanafadine Granted FDA Priority Review for the Treatment of ADHD Across Pediatric and Adult Populations - Patient Care Online
-
Weekly review: Centanafadine NDA, gene therapy approval, and more - Contemporary Pediatrics
-
FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD - HCPLive
-
New Drug Application Submitted for Centanafadine for Treatment of ADHD - Psychiatric Times
-
Centanafadine shows efficacy and tolerability for pediatric ADHD in phase 3 trial - Contemporary Pediatrics
-
Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults - Contemporary Pediatrics
-
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults - Yahoo Finance
-
Otsuka files for US approval for centanafadine in ADHD - The Pharma Letter
-
MedCheck: FDA to Consider Novel ADHD Drug; Semaglutide Fails to Slow Alzheimer’s Progression; and More - Psychiatry Online
-
Conversations in ADHD: Highlights From APSARD 2026 - Psychiatric Times
-
High-dose centanafadine safely, effectively reduces adolescent ADHD symptoms - Healio
-
Centanafadine Study: New ADHD Drug Effective for Adults and Kids - ADDitude
-
FDA accepts Otsuka’s centanafadine NDA for priority review - The Pharma Letter
-
FDA accepts priority review for Otsuka’s ADHD treatment centanafadine By Investing.com - Investing.com Australia
-
New ADHD Medications Discussed at APSARD 2026 - Psychiatric Times
-
The Cutting Edge of ADHD: Research News, MAHA Commission, and More - ADDitude
-
Centanafadine Shows Promise in Phase 3 Trials for Adolescent ADHD - HCPLive
-
Phase 3 Trial Data Supports Efficacy of Novel Treatment for ADHD in Adults - Psychiatric Times
-
Otsuka sees success in two phase 3 trials of centanafadine to treat ADHD - Healio
-
Triple Reuptake Inhibitor Centanafadine Looks Promising for Adult ADHD - Medical Professionals Reference
-
First-in-Class Norepinephrine, Dopamine, and Serotonin Reuptake Inhibitor for ADHD - Psychiatric Times
-
Novel ADHD Therapy More Tolerable, Less Effective Than Current Treatment Options - Drug Topics
-
Otsuka reports positive data from two Phase III ADHD treatment trials - Clinical Trials Arena
-
Focus on abuse risk may affect sales of non-stimulants for ADHD - Pharmaceutical Technology
-
Supernus’ depression drug improved symptoms in two hours in Phase IIa study - Clinical Trials Arena
-
NDT - Dove Medical Press
-
Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - Genetic Engineering and Biotechnology News
-
Otsuka to acquire Neurovance - ACS Publications
-
Otsuka acquires ADHD drug in $100M deal for Neurovance - BioPharma Dive
-
Emerging Therapies for Attention-Deficit/Hyperactivity Disorder - Psychiatrist.com
-
Otsuka to acquire Neurovance - C&EN
-
Centanafadine promising therapy for adults with attention-deficit or hyperactivity disorder - Medical Dialogues
-
Neurovance Completes Enrollment in Abuse Liability Study - drugdiscoverytrends.com
-
Otsuka Pharmaceuticals Acquires Neurovance - drugdiscoverytrends.com
-
You might be interested in…ADHD - Irish Medical Times
-
Qelbree’s recent approval for adults with ADHD highlights need for non-stimulant treatment options - Pharmaceutical Technology
-
High ADHD comorbidity rates offer opportunity for pipeline products to capture market: GlobalData - Express Pharma
-
Otsuka to acquire Neurovance in potential $250 million deal - Pharmafile
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.